var data={"title":"Esomeprazole: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Esomeprazole: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6133?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=esomeprazole-patient-drug-information\" class=\"drug drug_patient\">see &quot;Esomeprazole: Patient drug information&quot;</a> and <a href=\"topic.htm?path=esomeprazole-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Esomeprazole: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50836890\" class=\"block spa drugH1Div\"><span class=\"drugH1\">Special Alerts</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Proton Pump Inhibitors Safety Alert</span>\n      <span class=\"collapsible-date\">December 2017</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">Health Canada has issued a safety alert regarding the rare risk of subacute cutaneous lupus erythematosus with the use of proton pump inhibitors (PPI). This alert was prompted following a published article that examined reports in the FDA Adverse Event Reporting System.</p>\n        <p style=\"text-indent:0em;\">Health Canada is working with manufacturers to update the safety information to include these findings in all PPI-containing products. More information may be found at https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/safety-reviews/proton-pump-inhibitors-assessing-risk-type-skin-reaction.html.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166971\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Esomep-EZS;</li>\n      <li>GoodSense Esomeprazole [OTC];</li>\n      <li>NexIUM;</li>\n      <li>NexIUM 24HR Clear Minis [OTC];</li>\n      <li>NexIUM 24HR [OTC];</li>\n      <li>NexIUM I.V.</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166972\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Apo-Esomeprazole;</li>\n      <li>Mylan-Esomeprazole;</li>\n      <li>Nexium;</li>\n      <li>PMS-Esomeprazole DR</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166993\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Proton Pump Inhibitor;</li>\n      <li>\n        Substituted Benzimidazole</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166975\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> All dosing is expressed in terms of esomeprazole base, regardless of the salt associated with the dosing information. Esomeprazole strontium 24.65 mg is equivalent to 20 mg of esomeprazole base; esomeprazole strontium 49.3 mg is equivalent to 40 mg of esomeprazole base.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Erosive esophagitis (healing):</b> Oral: Esomeprazole magnesium, esomeprazole strontium: Initial: 20 to 40 mg once daily for 4 to 8 weeks; if incomplete healing, may continue for an additional 4 to 8 weeks; maintenance: 20 mg once daily (controlled studies did not extend beyond 6 months)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Heartburn (OTC labeling):</b> 20 mg once daily for 14 days (maximum: 20 mg/day); treatment may be repeated after 4 months if needed</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Symptomatic gastroesophageal reflux:</b> Oral: Esomeprazole magnesium, esomeprazole strontium: 20 mg once daily for 4 weeks; may consider an additional 4 weeks of treatment if symptoms do not resolve</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Treatment of GERD (short-term): </b> IV: 20 mg or 40 mg once daily. <b>Note:</b> Indicated only in cases where oral therapy is inappropriate or not possible; safety/efficacy &ge;10 days has not been established.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prevention of recurrent gastric or duodenal ulcer bleeding postendoscopy:</b> IV: 80 mg over 30 minutes, followed by 8 mg/hour continuous infusion for a total of 72 hours, then 40 mg <i>orally</i> once daily for 27 additional days (Sung, 2009) or may follow continuous infusion with any single daily-dose oral proton pump inhibitor (PPI) for a duration dictated by the underlying etiology (Barkun 2010). <b>Note:</b> The use of intermittent PPIs was found to be comparable with the use of continuous infusion PPIs in patients with high-risk endoscopic findings and may be preferred (Sachar 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Helicobacter pylori</i></b> <b> eradication:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Manufacturer labeling: Esomeprazole magnesium, esomeprazole strontium: 40 mg once daily administered with amoxicillin 1,000 mg <i>and</i> clarithromycin 500 mg twice daily for 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">American College of Gastroenterology guidelines (Chey 2007; Chey 2017):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Clarithromycin triple regimen: </i>20 to 40 mg twice daily in combination with clarithromycin 500 mg twice daily and either amoxicillin 1 g twice daily or metronidazole 500 mg 3 times daily; continue regimen for 14 days.<b> Note:</b> Avoid use of clarithromycin triple therapy in patients with risk factors for macrolide resistance (eg, prior macrolide exposure, local clarithromycin resistance rates &ge;15%, eradication rates with clarithromycin-based regimens &le;85%) (ACG [Chey 2017]; Fallone 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Bismuth quadruple regimen:</i> 20 mg twice daily in combination with tetracycline 500 mg 4 times daily, metronidazole 250 mg 4 times daily or 500 mg 3 or 4 times daily, and either bismuth subcitrate 120 to 300 mg 4 times daily or bismuth subsalicylate 300 mg 4 times daily; continue regimen for 10 to 14 days.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Concomitant regimen: </i>20 mg twice daily in combination with amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and either metronidazole or tinidazole 500 mg twice daily; continue regimen for 10 to 14 days.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Sequential regimen: </i>20 mg twice daily plus amoxicillin 1 g twice daily for 5 to 7 days; then continue esomeprazole along with clarithromycin 500 mg twice daily, and either metronidazole or tinidazole 500 mg twice daily for 5 to 7 days.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Hybrid regimen: </i>20 mg twice daily plus amoxicillin 1 g twice daily for 7 days; then continue esomeprazole and amoxicillin along with clarithromycin 500 mg twice daily, and either metronidazole or tinidazole 500 mg twice daily for 7 days.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Levofloxacin triple regimen:</i> 20 mg twice daily in combination with amoxicillin 1 g twice daily and levofloxacin 500 mg once daily; continue regimen for 10 to 14 days.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prevention of NSAID-induced gastric ulcers:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Esomeprazole magnesium, esomeprazole strontium: 20 to 40 mg once daily for up to 6 months; <b>Note:</b> 40 mg daily did not show additional benefit over 20 mg daily in clinical trials.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Treatment of NSAID-induced gastric ulcers</b> (off-label use): Oral: Esomeprazole magnesium: 20 mg once daily for 8 weeks (Goldstein 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pathological hypersecretory conditions (Zollinger-Ellison syndrome):</b> Oral: Esomeprazole magnesium, esomeprazole strontium: 40 mg twice daily; adjust regimen to individual patient needs; doses up to 240 mg daily have been administered</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2934196\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=esomeprazole-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Esomeprazole: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> All dosing is expressed in terms of esomeprazole base, regardless of the salt associated with the dosing information. Esomeprazole strontium is not recommended for use in pediatrics.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Symptomatic GERD:</b> Oral: Esomeprazole magnesium:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 1 to 11 years: 10 mg once daily for up to 8 weeks; <b>Note:</b> Safety and efficacy of doses &gt;1 mg/kg/day and/or therapy beyond 8 weeks have not been established.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adolescents 12 to 17 years: 20 mg once daily for up to 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Treatment of GERD (short-term):</b> IV: <b> Note:</b> Indicated only in cases where oral therapy is inappropriate or not possible; safety/efficacy &ge;10 days has not been established.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 1 month to &lt;1 year: 0.5 mg/kg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 1 to 17 years: &lt;55 kg: 10 mg once daily; &ge;55 kg: 20 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Erosive esophagitis (healing):</b> Oral: Esomeprazole magnesium:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 1 month to &lt;1 year: <b>Note:</b> Safety and efficacy of doses &gt;1.33 mg/kg/day and/or therapy beyond 6 weeks have not been established.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">3 to 5 kg: 2.5 mg once daily for up to 6 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&gt;5 to 7.5 kg: 5 mg once daily for up to 6 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&gt;7.5 to 12 kg: 10 mg once daily for up to 6 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 1 to 11 years: <b>Note:</b> Safety and efficacy of doses &gt;1 mg/kg/day and/or therapy beyond 8 weeks have not been established.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&lt;20 kg: 10 mg once daily for 8 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&ge;20 kg: 10 to 20 mg once daily for 8 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adolescents 12 to 17 years: 20 to 40 mg once daily for 4 to 8 weeks</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166976\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166977\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Esomeprazole magnesium: Mild-to-severe impairment: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Esomeprazole strontium:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mild-to-moderate impairment: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Severe impairment: Use is not recommended (has not been studied).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Mild-to-severe impairment: No dosage adjustment necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166978\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Safety and efficacy not established in children with hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Mild to moderate impairment (Child-Pugh class A or B): No dosage adjustment necessary. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Severe impairment (Child-Pugh class C): Maximum: 20 mg  daily.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Treatment of GERD (short-term):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Mild to moderate impairment (Child-Pugh class A or B): No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Severe impairment (Child-Pugh class C): Dose should not exceed 20 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Prevention of recurrent gastric or duodenal ulcer bleeding postendoscopy:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Mild to moderate impairment (Child-Pugh class A or B):  80 mg over 30 minutes, followed by a maximum continuous infusion of 6 mg/hour for a total of 72 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Severe impairment (Child-Pugh class C): 80 mg over 30 minutes, followed by a maximum continuous infusion of 4 mg/hour for a total of 72 hour</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166946\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule Delayed Release, Oral, as magnesium [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">GoodSense Esomeprazole: 20 mg [gluten free; contains brilliant blue fcf (fd&amp;c blue #1)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">NexIUM: 20 mg, 40 mg [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c red #40, fd&amp;c yellow #10 (quinoline yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">NexIUM 24HR: 20 mg [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c red #40]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">NexIUM 24HR Clear Minis: 20 mg [contains corn starch, fd&amp;c blue #2 (indigotine), fd&amp;c blue #2 aluminum lake, fd&amp;c red #40]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 20 mg, 40 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule Delayed Release, Oral, as strontium: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 24.65 mg [DSC], 49.3 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Kit, Oral, as magnesium [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Esomep-EZS: 20 mg [contains brilliant blue fcf (fd&amp;c blue #1), sodium benzoate]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Packet, Oral, as magnesium [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">NexIUM: 2.5 mg (30 ea); 5 mg (30 ea); 10 mg (30 ea); 20 mg (30 ea); 40 mg (30 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous, as sodium [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">NexIUM I.V.: 20 mg (1 ea [DSC]); 40 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 20 mg (1 ea); 40 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Delayed Release, Oral, as magnesium [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">NexIUM 24HR: 20 mg [contains fd&amp;c blue #2 aluminum lake, fd&amp;c red #40 aluminum lake]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166932\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22149198\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Esomeprazole strontium 49.3 mg is equivalent to 40 mg of esomeprazole base.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Esomep-EZS Kit contains delayed release capsules, packaged with Pill Swallowing Spray</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5940148\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Strength expressed as base</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet, extended release, as magnesium:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Nexium: 40 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15241701\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Esomeprazole strontium delayed release capsules<a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202342s003lbl.pdf#page=29&amp;token=dztfn3HYGfLRHPylZ0kQ2J4uDWeoLl68yAlpgFyBlr5UY6pA3zK4RiEYPc1HLkU8GcUNWpzJKQByxoA1eAsuQllTPkdp+/nejMyFPmIVzHK+jfjX/yYsYLBx956jFDBK&amp;TOPIC_ID=9104\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202342s003lbl.pdf#page=29</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">NexIUM capsules, granules for oral suspension: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM322355.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/9BK5et6GehFK9IioulPK5W3bRpIqFIHgIWqEMHgdZv1A==&amp;TOPIC_ID=9104\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM322355.pdf</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166948\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Capsule: Swallow whole and take at least 1 hour before eating (best if taken before breakfast). Capsule can be opened and contents mixed with 1 tablespoon of applesauce. Swallow immediately; mixture should not be chewed or warmed. For patients with difficulty swallowing, use of granules may be more appropriate.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Granules: Empty the 2.5 mg or 5 mg packet into a container with 5 mL of water or the 10 mg, 20 mg, or 40 mg packet into a container with 15 mL of water and stir; leave 2 to 3 minutes to thicken. Stir and drink within 30 minutes. If any medicine remains after drinking, add more water, stir and drink immediately.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tablet: Swallow whole; do not crush or chew; administer with a full glass of water before breakfast in the morning.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tablet [Canadian product]: Swallow whole with water or may be dispersed in a half a glass of noncarbonated water. Stir until tablets disintegrate, and drink the liquid with pellets immediately or within 30 minutes. Do not chew or crush pellets. After drinking, rinse glass with water and drink.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Flush line prior to and after administration with NS, LR, or D<sub>5</sub>W.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children: Administer by intermittent infusion (10 to 30 minutes); the manufacturer recommends that children receive intravenous esomeprazole by intermittent infusion only.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Treatment of GERD: May be administered by injection (&ge;3 minutes), or intermittent infusion (10 to 30 minutes)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Prevention of recurrent gastric or duodenal ulcer bleeding postendoscopy: Administer the loading dose over 30 minutes, followed by the continuous infusion at a rate of 8 mg/hour over 71.5 hours (adjust rate of continuous infusion in patients with hepatic dysfunction)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nasogastric tube:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Capsule: Open capsule and place intact granules into a 60 mL catheter-tip syringe; mix with 50 mL of water. Replace plunger and shake vigorously for 15 seconds. Ensure that no granules remain in syringe tip. Do not administer if pellets dissolve or disintegrate. Use immediately after preparation. After administration, flush nasogastric tube with additional water.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Granules: Delayed release oral suspension granules can also be given by nasogastric or gastric tube. If using a 2.5 mg or 5 mg packet, first add 5 mL of water to a catheter-tipped syringe, then add granules from packet. If using a 10 mg, 20 mg, or 40 mg packet, first add 15 mL of water to a catheter-tipped syringe, then add granules from packet. Shake the syringe, leave 2 to 3 minutes to thicken. Shake the syringe and administer through nasogastric or gastric tube (size 6 French or greater) within 30 minutes. Refill the syringe with equal amount (5 mL or 15 mL) of water, shake and flush nasogastric/gastric tube.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tablet [Canadian product]: Dispersed tablets can also be given by nasogastric tube (size 8 to 20 French) using a 25 to 60 mL disposable syringe. Disperse tablet in 50 mL of water. After administration, flush with additional 25 to 50 mL of water to clear the syringe and tube. In larger nasogastric feeding tubes (ie, size 14 French or greater), the dispersion volume may be reduced to 25 mL.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14472623\" class=\"block uica drugH1Div\"><span class=\"drugH1\">Usual Infusion Concentrations: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>IV infusion:</b> 20 mg in 50 mL (concentration: 0.4 mg/mL) <b>or</b> 40 mg in 50 mL (concentration: 0.8 mg/mL) of D<sub>5</sub>W, LR, or NS</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14472624\" class=\"block uicp drugH1Div\"><span class=\"drugH1\">Usual Infusion Concentrations: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>IV infusion:</b> 0.4 mg/mL <b>or</b> 0.8 mg/mL </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166947\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Esomeprazole magnesium and esomeprazole strontium:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Gastroesophageal reflux disease (Rx only): </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Healing of erosive esophagitis:</b> Short-term (4 to 8 weeks) treatment of erosive esophagitis</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Maintenance of healing of erosive esophagitis:</b> Maintaining symptom resolution and healing of erosive esophagitis</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Symptomatic gastroesophageal reflux disease:</b> Short-term (4 to 8 weeks) treatment of symptomatic gastroesophageal reflux disease (GERD)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Helicobacter pylori</i></b>\n      <b> eradication (Rx only):</b> As part of a multidrug regimen for <i>Helicobacter pylori</i> eradication in patients with duodenal ulcer disease (active or history of within the past 5 years)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Risk reduction of nonsteroidal anti-inflammatory drug-associated gastric ulcer (Rx only):</b> Prevention of gastric ulcers associated with continuous NSAID therapy in patients at risk (age &ge;60 years and/or history of gastric ulcer)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pathological hypersecretory conditions, including Zollinger-Ellison syndrome (Rx only):</b> Treatment (long-term) of pathological hypersecretory conditions including Zollinger-Ellison syndrome</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Esomeprazole magnesium:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Heartburn (OTC labeling):</b> Treatment of frequent heartburn (&ge;2 days per week).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">IV: Esomeprazole sodium:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Gastroesophageal reflux disease (Rx only):</b> Short-term (&le;10 days) treatment of gastroesophageal reflux disease (GERD) with erosive esophagitis in pediatric patients 1 month to 17 years of age and adults when oral therapy is not possible or appropriate</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Risk reduction of ulcer rebleeding postprocedure (Rx only):</b> Decrease the risk of rebleeding postendoscopy for acute bleeding gastric or duodenal ulcers in adults</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50558978\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Stress ulcer prophylaxis in critically-ill patients; Treatment of NSAID-induced gastric ulcers</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5730363\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Esomeprazole may be confused with ARIPiprazole, omeprazole</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">NexIUM may be confused with NexAVAR</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Proton pump inhibitors are identified in the Beers Criteria as potentially inappropriate medications to be avoided (as scheduled use for more than 8 weeks) in patients 65 years and older due to its risk of <i>C. difficile</i> infection and bone loss/fractures. Use more than 8 weeks should be avoided <i>unless</i> given for high-risk patients (eg, oral corticosteroid or chronic NSAID use), patients with erosive esophagitis, Barrett&rsquo;s esophagitis, a pathological hypersecretory condition, or if the patient has demonstrated a need for maintenance therapy (eg, failure of drug discontinuation trial or failure of H2 blockers) (Beers Criteria [AGS 2015]).</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166938\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Unless otherwise specified, percentages represent adverse reactions identified in clinical trials evaluating the oral formulation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%: Central nervous system: Headache (2% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Irritability (infants: &ge;5%), dizziness (intravenous: &le;3%; oral: &lt;1%), vertigo (intravenous: &le;3%), drowsiness (children: 2%; adults: &lt;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Pruritus (intravenous: 1%; oral: &lt;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Altered thyroid hormone levels (increased thyroxine: &le;1%), decreased serum potassium (&le;1%), decreased serum sodium (&le;1%), decreased thyroid hormones (thyroxine: &le;1%), increased gastrin (&le;1%), increased serum potassium (&le;1%), increased serum sodium (&le;1%), increased thyroid stimulating hormone level (&le;1%), increased uric acid (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Flatulence (intravenous: 10%; oral: &ge;1%), diarrhea (2% to 4%), abdominal pain (1% to 6%), nausea (intravenous: 6%; oral: &ge;1% to 2%), vomiting (infants: 1% to &ge;5%; adults: &lt;1%), xerostomia (intravenous: 4%; oral: &ge;1%), constipation (intravenous: 3%; oral: &ge;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Change in platelet count (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum alkaline phosphatase (&le;1%), increased serum ALT (&le;1%), increased serum AST (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Injection site reaction (intravenous: 2% to 4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Increased serum creatinine (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Cough (intravenous: 1%; oral: &lt;1%), tachypnea (infants, oral: 1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (intravenous: 4%; oral: &lt;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Esophageal varices</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Barrett esophagus, duodenitis, esophageal stenosis, esophageal ulcer, esophagitis, gastritis, mucosal discoloration</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Benign polyp</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Benign nodule</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Acne vulgaris, acute interstitial nephritis, aggressive behavior, ageusia, agitation, agranulocytosis, albuminuria, alopecia, altered sense of smell, anaphylactic shock, anaphylaxis, anemia, angioedema, anorexia, apathy, aphthous stomatitis, arthralgia, arthropathy, back pain, blurred vision, bone fracture, bronchospasm, candidiasis (urogenital), cervical lymphadenopathy, change in bowel habits, chest pain, <i>Clostridium difficile</i>-associated diarrhea, colitis (microscopic), confusion, conjunctivitis, cutaneous lupus erythematous (including exacerbations), cyanocobalamin deficiency, cystitis, depression, dermatitis, diaphoresis, dysgeusia, dysmenorrhea, dyspepsia, dysphagia, dyspnea, dysuria, edema, enlargement of abdomen, epigastric pain, epistaxis, eructation, erythema multiforme, erythematous rash, exacerbation of arthritis, exacerbation of asthma, facial edema, fatigue, fibromyalgia syndrome, flu-like symptoms, flushing, frequent bowel movements, fungal infection, gastroenteritis, gastrointestinal dysplasia, gastrointestinal hemorrhage, genital candidiasis, GI moniliasis, glycosuria, goiter, gynecomastia, hallucination, hematuria, hepatic encephalopathy, hepatic failure, hepatitis, hepatotoxicity (idiosyncratic) (Chalasani 2014), hernia, hiccups, hot flash, hyperbilirubinemia, hyperhidrosis, hypersensitivity reaction, hypertension, hypertonia, hyperuricemia, hypochromic anemia, hypoesthesia, hypomagnesemia (with or without hypocalcemia and/or hypokalemia), hyponatremia, impotence, increased appetite, increased thirst, insomnia, interstitial nephritis, jaundice, laryngeal edema, leukocytosis, leukopenia, maculopapular rash, malaise, melena, menstrual disease, migraine, mouth disease, muscle cramps, myalgia, myasthenia, nervousness, otalgia, otitis media, pain, pancreatitis, pancytopenia, paresthesia, pathological fracture due to osteoporosis, peripheral edema, pharyngeal disease, pharyngitis, polymyalgia rheumatica, polyuria, pruritus ani, rectal disease, renal disease (chronic; [Lazarus 2016]), rhinitis, rigors, sinusitis, skin photosensitivity, skin rash, sleep disorder, Stevens-Johnson syndrome, stomatitis, systemic lupus erythematosus (including exacerbations), tachycardia, thrombocytopenia, tinnitus, tongue disease, tongue edema, toxic epidermal necrolysis, tremor, urinary frequency, urine abnormality, urticaria, vaginitis, vertigo, visual disturbance, visual field defect, weakness, weight gain, weight loss</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166951\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity (eg, anaphylaxis, anaphylactic shock, angioedema, bronchospasm, acute interstitial nephritis, urticaria) to esomeprazole, other substituted benzimidazole proton pump inhibitors, or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Canadian labeling: Additional contraindications (not in US labeling): Concurrent use with rilprivirine.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OTC labeling: When used for self-medication (OTC), do not use if you have trouble or pain when swallowing food; vomiting with blood, or bloody or black stools; heartburn with lightheadedness, dizziness, or sweating; chest pain or shoulder pain with shortness of breath, sweating, pain spreading to arms, neck or shoulders, or lightheadedness; frequent chest pain</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166936\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Carcinoma: No reports of enterochromaffin-like (ECL) cell carcinoids, dysplasia, or neoplasia have occurred.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; <i>Clostridium difficile</i>-associated diarrhea (CDAD): Use of proton pump inhibitors (PPIs) may increase risk of CDAD, especially in hospitalized patients; consider CDAD diagnosis in patients with persistent diarrhea that does not improve. Use the lowest dose and shortest duration of PPI therapy appropriate for the condition being treated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cutaneous and systemic lupus erythematosus: Has been reported as new onset or exacerbation of existing autoimmune disease; most cases were cutaneous lupus erythematosus (CLE), most commonly, subacute CLE (occurring within weeks to years after continuous therapy). Systemic lupus erythematosus (SLE) is less common (typically occurs within days to years after initiating treatment) and occurred primarily in young adults up to the elderly. Discontinue therapy if signs or symptoms of CLE or SLE occur and refer to specialist for evaluation; most patients improve 4 to 12 weeks after discontinuation of esomeprazole.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fractures: Increased incidence of osteoporosis-related bone fractures of the hip, spine, or wrist may occur with proton pump inhibitor (PPI) therapy. Patients on high-dose or long-term therapy (&ge;1 year) should be monitored. Use the lowest effective dose for the shortest duration of time, use vitamin D and calcium supplementation, and follow appropriate guidelines to reduce risk of fractures in patients at risk.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal infection (eg, Salmonella, Campylobacter): Use of proton pump inhibitors may increase risk of these infections.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypomagnesemia: Reported rarely, usually with prolonged PPI use of &ge;3 months (most cases &gt;1 year of therapy). May be symptomatic or asymptomatic; severe cases may cause tetany, seizures, and cardiac arrhythmias. Consider obtaining serum magnesium concentrations prior to beginning long-term therapy, especially if taking concomitant digoxin, diuretics, or other drugs known to cause hypomagnesemia; and periodically thereafter. Hypomagnesemia may be corrected by magnesium supplementation, although discontinuation of esomeprazole may be necessary; magnesium levels typically return to normal within 1 week of stopping.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Interstitial nephritis: Acute interstitial nephritis has been observed in patients taking PPIs; may occur at any time during therapy and is generally due to an idiopathic hypersensitivity reaction. Discontinue if acute interstitial nephritis develops.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vitamin B<sub>12</sub> deficiency: Prolonged treatment (&ge;2 years) may lead to vitamin B<sub>12</sub> malabsorption and subsequent vitamin B<sub>12</sub> deficiency. The magnitude of the deficiency is dose-related and the association is stronger in females and those younger in age (&lt;30 years); prevalence is decreased after discontinuation of therapy (Lam 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastric malignancy: Relief of symptoms does not preclude the presence of a gastric malignancy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Patients with severe hepatic impairment may require dosage reductions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Pharmacokinetics of esomeprazole are not expected to be altered in renal impairment; dosage adjustments are not necessary for any degree of renal impairment when using esomeprazole magnesium or esomeprazole sodium. However, since pharmacokinetics of the strontium may be reduced in mild to moderate renal impairment, esomeprazole strontium is not recommended for use in severe impairment (has not been studied).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Clopidogrel: Proton pump inhibitors (PPIs) may diminish the therapeutic effect of clopidogrel, thought to be due to reduced formation of the active metabolite of clopidogrel. The manufacturer of clopidogrel recommends either avoidance of both omeprazole (even when scheduled 12 hours apart) and esomeprazole or use of a PPI with comparatively less effect on the active metabolite of clopidogrel (eg, pantoprazole). In contrast to these warnings, others have recommended the continued use of PPIs, regardless of the degree of inhibition, in patients with a history of GI bleeding or multiple risk factors for GI bleeding who are also receiving clopidogrel since no evidence has established clinically meaningful differences in outcome; however, a clinically significant interaction cannot be excluded in those who are poor metabolizers of clopidogrel (Abraham 2010; Levine 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Bioavailability may be increased in elderly patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Esomeprazole strontium: Strontium competes with calcium for intestinal absorption and is incorporated into bone; use of esomeprazole strontium in pediatric patients is not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Intravenous: Safety and efficacy of IV treatment for GERD beyond 10 days have not been established; transition from IV to oral therapy as soon possible.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: <i>Helicobacter pylori</i> eradication: Short-term combination therapy (&le;7 days) has been associated with a higher incidence of treatment failure. The American College of Gastroenterology recommends 10 to 14 days of therapy (triple or quadruple) for eradication of <i>H. pylori</i> (Chey 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Laboratory test interference: Serum chromogranin A (CgA) levels increase secondary to drug-induced decreases in gastric acid; may cause false-positive results in diagnostic investigations for neuroendocrine tumors. Temporarily stop esomeprazole treatment &ge;14 days before CgA test; if CgA level high, repeat test to confirm. Use same commercial laboratory for testing to prevent variable results.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Self-medication (OTC use): When used for self-medication (OTC), notify health care provider before use if any of the following are present: heartburn for &gt;3 months; frequent wheezing, particularly with heartburn; unexplained weight loss; nausea or vomiting; or stomach pain. Discontinue use and notify health care provider if heartburn continues or worsens; diarrhea occurs; if &gt;14 days of therapy is needed; or if &gt;1 course of therapy is needed every 4 months.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166987\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2C19 (major), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2C19 (weak)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166940\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9104&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acalabrutinib: Proton Pump Inhibitors may decrease the serum concentration of Acalabrutinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamine: Proton Pump Inhibitors may increase the absorption of Amphetamine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Atazanavir: Proton Pump Inhibitors may decrease the serum concentration of Atazanavir.  Management: See full drug interaction monograph for details.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bisphosphonate Derivatives: Proton Pump Inhibitors may diminish the therapeutic effect of Bisphosphonate Derivatives. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosutinib: Proton Pump Inhibitors may decrease the serum concentration of Bosutinib.  Management: Consider alternatives to proton pump inhibitors, such as antacids or H2 receptor antagonists.  Administer alternative agents more than 2 hours before or after bosutinib.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capecitabine: Proton Pump Inhibitors may diminish the therapeutic effect of Capecitabine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cefditoren: Proton Pump Inhibitors may decrease the serum concentration of Cefditoren.  Management: If possible, avoid use of cefditoren with proton pump inhibitors (PPIs). Consider alternative methods to minimize/control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of PPIs can not be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cefpodoxime: Proton Pump Inhibitors may decrease the serum concentration of Cefpodoxime. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cefuroxime: Proton Pump Inhibitors may decrease the absorption of Cefuroxime. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cilostazol: CYP2C19 Inhibitors may increase the serum concentration of Cilostazol.  Management: Consider reducing the cilostazol dose to 50 mg twice daily in patients who are also receiving inhibitors of CYP2C19.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Citalopram: Esomeprazole may increase the serum concentration of Citalopram. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clopidogrel: Esomeprazole may diminish the antiplatelet effect of Clopidogrel. Esomeprazole may decrease serum concentrations of the active metabolite(s) of Clopidogrel.  Management: Clopidogrel prescribing information recommends avoiding concurrent use with esomeprazole. Rabeprazole or pantoprazole may be lower-risk alternatives to esomeprazole.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C19 Inducers (Strong): May increase the metabolism of CYP2C19 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cysteamine (Systemic): Proton Pump Inhibitors may diminish the therapeutic effect of Cysteamine (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabigatran Etexilate: Proton Pump Inhibitors may decrease serum concentrations of the active metabolite(s) of Dabigatran Etexilate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP2C19 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP2C19 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: Proton Pump Inhibitors may decrease the serum concentration of Dabrafenib. Dabrafenib may decrease the serum concentration of Proton Pump Inhibitors.  Management: Seek alternatives to the proton pump inhibitor when possible.  If concomitant therapy cannot be avoided, monitor for diminished effects of both drugs.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: Proton Pump Inhibitors may decrease the serum concentration of Dasatinib.  Management: Antacids (taken 2 hours before or after dasatinib administration) can be used in place of the proton pump inhibitor if some acid-reducing therapy is needed.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Delavirdine: Proton Pump Inhibitors may decrease the serum concentration of Delavirdine.  Management: Chronic therapy with proton pump inhibitors (PPIs) should be avoided in patients treated with delavirdine.  The clinical significance of short-term PPI therapy with delavirdine is uncertain, but such therapy should be undertaken with caution.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dexmethylphenidate: Proton Pump Inhibitors may increase the absorption of Dexmethylphenidate. Specifically, proton pump inhibitors may interfere with the normal release of drug from the extended-release capsules (Focalin XR brand), which could result in both increased absorption (early) and decreased delayed absorption. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dextroamphetamine: Proton Pump Inhibitors may increase the absorption of Dextroamphetamine. Specifically, the dextroamphetamine absorption rate from mixed amphetamine salt extended release (XR) capsules may be increased in the first hours after dosing. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CYP2C19 Substrates (High risk with Inducers). Conversely, concentrations of active metabolites may be increased for those drugs activated by CYP2C19. Management: Concurrent use of enzalutamide with CYP2C19 substrates that have a narrow therapeutic index should be avoided.  Use of enzalutamide and any other CYP2C19 substrate should be performed with caution and close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Erlotinib: Proton Pump Inhibitors may decrease the serum concentration of Erlotinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fluconazole: May increase the serum concentration of Proton Pump Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gefitinib: Proton Pump Inhibitors may decrease the serum concentration of Gefitinib.  Management: Avoid use of proton pump inhibitors (PPIs) with gefitinib when possible. If required, administer gefitinib 12 hours after administration of the PPI or 12 hours before the next dose of the PPI.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indinavir: Proton Pump Inhibitors may decrease the serum concentration of Indinavir. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iron Salts: Proton Pump Inhibitors may decrease the absorption of Iron Salts. <b> Exceptions: </b>Ferric Carboxymaltose; Ferric Citrate; Ferric Gluconate; Ferric Hydroxide Polymaltose Complex; Ferric Pyrophosphate Citrate; Ferumoxytol; Iron Dextran Complex; Iron Isomaltoside; Iron Sucrose.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Itraconazole: Proton Pump Inhibitors may decrease the serum concentration of Itraconazole. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ketoconazole (Systemic): Proton Pump Inhibitors may decrease the serum concentration of Ketoconazole (Systemic). Ketoconazole (Systemic) may increase the serum concentration of Proton Pump Inhibitors. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ledipasvir: Proton Pump Inhibitors may decrease the serum concentration of Ledipasvir.  Management: PPI doses equivalent to omeprazole 20 mg or lower may be given with ledipasvir under fasted conditions. Administration with higher doses of PPIs, 2 hours after a PPI, or in combination with food and PPIs may reduce ledipasvir bioavailability.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lumacaftor: May decrease the serum concentration of CYP2C19 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mesalamine: Proton Pump Inhibitors may diminish the therapeutic effect of Mesalamine. Proton pump inhibitor-mediated increases in gastrointestinal pH may cause the premature release of mesalamine from specific sustained-release mesalamine products.  Management: Consider avoiding concurrent administration of high-dose proton pump inhibitors (PPIs) with sustained-release mesalamine products.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrexate: Proton Pump Inhibitors may increase the serum concentration of Methotrexate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: Proton Pump Inhibitors may increase the absorption of Methylphenidate. Specifically, proton pump inhibitors may interfere with the normal release of drug from the extended-release capsules (Ritalin LA brand), which could result in both increased absorption (early) and decreased delayed absorption. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): Proton Pump Inhibitors may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, the absorption of iron may be decreased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mycophenolate: Proton Pump Inhibitors may decrease the serum concentration of Mycophenolate. Specifically, concentrations of the active mycophenolic acid may be reduced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nelfinavir: Proton Pump Inhibitors may decrease serum concentrations of the active metabolite(s) of Nelfinavir. Proton Pump Inhibitors may decrease the serum concentration of Nelfinavir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neratinib: Proton Pump Inhibitors may decrease the serum concentration of Neratinib. Specifically, proton pump inhibitors may reduce neratinib absorption. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nilotinib: Proton Pump Inhibitors may decrease the serum concentration of Nilotinib.  Management: Avoid this combination when possible since separation of doses is not likely to be an adequate method of minimizing the interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PAZOPanib: Proton Pump Inhibitors may decrease the serum concentration of PAZOPanib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Posaconazole: Proton Pump Inhibitors may decrease the serum concentration of Posaconazole. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Raltegravir: Proton Pump Inhibitors may increase the serum concentration of Raltegravir. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RifAMPin: May decrease the serum concentration of Esomeprazole.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rilpivirine: Proton Pump Inhibitors may decrease the serum concentration of Rilpivirine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Riociguat: Proton Pump Inhibitors may decrease the serum concentration of Riociguat. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Risedronate: Proton Pump Inhibitors may diminish the therapeutic effect of Risedronate. Proton Pump Inhibitors may increase the serum concentration of Risedronate. This applies specifically to use of delayed-release risedronate. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Saquinavir: Proton Pump Inhibitors may increase the serum concentration of Saquinavir. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Secretin: Proton Pump Inhibitors may diminish the diagnostic effect of Secretin. Specifically, use of PPIs may cause a hyperresponse in gastrin secretion in response to secretin stimulation testing, falsely suggesting gastrinoma.  Management: Avoid concomitant use of proton pump inhibitors (PPIs) and secretin, and discontinue PPIs several weeks prior to secretin administration, with the duration of separation determined by the specific PPI. See full monograph for details.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of Esomeprazole.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Systemic): Proton Pump Inhibitors may increase the serum concentration of Tacrolimus (Systemic).  Management: Tacrolimus dose adjustment may be required. Rabeprazole, pantoprazole, or selected H2-receptor antagonists (i.e., ranitidine or famotidine) may be less likely to interact. Genetic testing may predict patients at highest risk.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tipranavir: May decrease the serum concentration of Proton Pump Inhibitors. These data are derived from studies with Ritonavir-boosted Tipranavir.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Velpatasvir: Proton Pump Inhibitors may decrease the serum concentration of Velpatasvir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Esomeprazole may increase the serum concentration of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Voriconazole: May increase the serum concentration of Proton Pump Inhibitors. Proton Pump Inhibitors may increase the serum concentration of Voriconazole. Management: In patients receiving omeprazole 40 mg/day or greater, reduce omeprazole dose by half when initiating voriconazole.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166968\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Prolonged treatment (&ge;2 years) may lead to malabsorption of dietary vitamin B<sub>12</sub> and subsequent vitamin B<sub>12</sub> deficiency (Lam, 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166955\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in some animal reproduction studies. An increased risk of hypospadias was reported following maternal use of proton pump inhibitors (PPIs) during pregnancy (Anderka, 2012), but this was based on a small number of exposures and the same association was not found in another study (Erichsen, 2012). An increased risk of major birth defects following maternal use of PPIs during pregnancy was not observed in an additional study (Pasternak, 2010). Esomeprazole is the s-isomer of omeprazole; refer to the omeprazole monograph for additional information. When treating GERD in pregnancy, PPIs may be used when clinically indicated (Katz, 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166956\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Esomeprazole and strontium (limited data) are excreted in breast milk. According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother. Esomeprazole is the s-isomer of omeprazole, and omeprazole is excreted in breast milk; refer to Omeprazole monograph for additional information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166957\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Take at least 1 hour before meals; best if taken before breakfast.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166944\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Susceptibility testing recommended in patients who fail <i>H. pylori</i> eradication regimen. Monitor for rebleeding in patients with peptic ulcer bleed. For patients expected to be on prolonged therapy or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (eg, diuretics), consider monitoring magnesium levels prior to initiation of treatment and periodically thereafter.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166935\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Proton pump inhibitor suppresses gastric acid secretion by inhibition of the H<sup>+</sup>/K<sup>+</sup>-ATPase in the gastric parietal cell. Esomeprazole is the S-isomer of omeprazole.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166950\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>dss</sub>: 16 L </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 97% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic via CYP2C19 primarily and (to a lesser extent) via 3A4 to hydroxy, desmethyl, and sulfone metabolites (all inactive)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Oral: 64 after a single dose; 90% with repeat dosing </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants: 0.93 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children 1 to 5 years: 0.42 to 0.74 hours (Zhao 2006) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children 6 to 11 years: 0.73 to 0.88 hours (Zhao 2006) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adolescents 12 to 17 years: 0.82 to 1.22 hours (Li 2006) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: ~1 to 1.5 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants: Median: 3 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children 1 to 5 years: 1.33 to 1.44 hours (Zhao 2006) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children 6 to 11 years: 1.75 to 1.79 hours (Zhao 2006) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adolescents 12 to 17 years: 1.96 to 2.04 hours (Li 2006) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: 1.5 to 2 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (80%, primarily as inactive metabolites; &lt;1% as active drug); feces (20%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Clearance (with repeated dosing): </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children 1 to 5 years: 6 to 19.44 L/hour (Zhao 2006) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children 6 to 11 years: 7.84 to 9.22 L/hour (Zhao 2006) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adolescents 12 to 17 years: 8.36 to 15.88 L/hour (Li 2006) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166954\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule, delayed release</b> (Esomeprazole Magnesium Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (30): $266.01</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (30): $266.45</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule, delayed release</b> (Esomeprazole Strontium Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">49.3 mg (30): $289.99</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule, delayed release</b> (GoodSense Esomeprazole Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (14): $3.54</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule, delayed release</b> (NexIUM 24HR Clear Minis Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (14): $10.74</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule, delayed release</b> (NexIUM 24HR Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (14): $9.84</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule, delayed release</b> (NexIUM Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (90): $903.35</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (90): $903.35</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Esomep-EZS Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (1): $393.15</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Pack</b> (NexIUM Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5 mg (30): $325.22</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (30): $325.22</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (30): $325.22</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (30): $325.22</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (30): $325.22</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Esomeprazole Sodium Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (1): $41.88</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (1): $41.88</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (NexIUM I.V. Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (1): $53.58</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, EC</b> (NexIUM 24HR Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (14): $10.74</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166958\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Aesopra (PH);</li>\n      <li>Alton (LK);</li>\n      <li>Ameprazole (VN);</li>\n      <li>Axiago (ES);</li>\n      <li>Carbum (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Ceso (IN);</li>\n      <li>Emanera (UA);</li>\n      <li>Emazole (IE);</li>\n      <li>Emep (PH);</li>\n      <li>Emess (LK);</li>\n      <li>Emozul (GB);</li>\n      <li>Emparis (VN);</li>\n      <li>Empel (LK);</li>\n      <li>Escadra (LV);</li>\n      <li>Esofag (IN);</li>\n      <li>Esofax (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Esoflux (PH);</li>\n      <li>Esogas IVF (VN);</li>\n      <li>Esoget DRT (PH);</li>\n      <li>Esola (ID);</li>\n      <li>Esomax (ID);</li>\n      <li>Esomep (BD, PH);</li>\n      <li>Esopra (BD);</li>\n      <li>Esorest (IN);</li>\n      <li>Esoroxen (KR);</li>\n      <li>Esoxium (VN);</li>\n      <li>Esoz-20 (ET, ZW);</li>\n      <li>Esoz-40 (ZW);</li>\n      <li>Exmezol (KR);</li>\n      <li>Exocid (ID);</li>\n      <li>Exozole (KR);</li>\n      <li>Exzium (LK);</li>\n      <li>Ignis (IN);</li>\n      <li>Inexium (FR);</li>\n      <li>Maxima (BD);</li>\n      <li>Nedox (CO, PE);</li>\n      <li>Neksium (IN, UA);</li>\n      <li>Nemeol (KR);</li>\n      <li>Neopral (PE);</li>\n      <li>Nepramel (IE);</li>\n      <li>Nexazol (KR);</li>\n      <li>Nexazole (IE);</li>\n      <li>Nexiam (BE, LU);</li>\n      <li>Nexipra (KR);</li>\n      <li>Nexird (KR);</li>\n      <li>Nexium (AE, AR, AT, AU, BB, BF, BG, BH, BJ, BM, BO, BR, BS, BZ, CH, CI, CL, CN, CO, CU, CY, CZ, DE, DK, EE, ES, ET, FI, GB, GH, GM, GN, GR, GY, HK, HR, ID, IE, IL, IS, IT, JM, JO, JP, KE, KR, KW, LB, LK, LR, LT, LV, MA, ML, MR, MT, MU, MW, MY, NE, NG, NL, NO, NZ, PE, PH, PL, PR, PT, PY, QA, RO, RU, SA, SC, SD, SE, SG, SI, SK, SL, SN, SR, TH, TN, TR, TT, TW, TZ, UG, UY, VE, VN, ZA, ZM, ZW);</li>\n      <li>Nexium IV (MX);</li>\n      <li>Nexium-MUPS (MX);</li>\n      <li>Nexmezol (LV);</li>\n      <li>Nexpa (KR);</li>\n      <li>Nexpro (IN, PH, ZW);</li>\n      <li>Nexpro-20 (ET, TZ);</li>\n      <li>Nexpro-40 (TZ);</li>\n      <li>Nexum (PK);</li>\n      <li>Pamezone (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Pemozar (UA);</li>\n      <li>Peprazom (PH);</li>\n      <li>Prazia (BD);</li>\n      <li>Raciper (IN);</li>\n      <li>S-Omipin (PH);</li>\n      <li>Sompraz (IN);</li>\n      <li>Sompraz IV (TZ);</li>\n      <li>Ulcium (EC);</li>\n      <li>Xsom (PH);</li>\n      <li>Zoleric (LK);</li>\n      <li>Zutura (EC)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Abraham NS, Hlatky MA, Antman EM, et al, &ldquo;ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use: A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents,&rdquo; <i>Circulation</i>, 2010, 122(24):2619-33.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/21060077/pubmed\" target=\"_blank\" id=\"21060077\">21060077</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc.</i> 2015;63(11):2227-2246. doi:10.1111/jgs.13702.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/26446832/pubmed\" target=\"_blank\" id=\"26446832\">26446832</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderka M, Mitchell AA, Louik C, et al, &quot;Medications Used to Treat Nausea and Vomiting of Pregnancy and the Risk of Selected Birth Defects,&quot; <i>Birth Defects Res A Clin Mol Teratol</i>, 2012, 94(1):22-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/22102545/pubmed\" target=\"_blank\" id=\"22102545\">22102545</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Andersson T, Hasan-Alin M, Hasselgren G, et al, &ldquo;Drug Interactions Studies With Esomeprazole, the (S)-Isomer of Omeprazole,&rdquo; <i>Clin Pharmacokinet</i>, 2001, 40(7):523-37.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/11510629/pubmed\" target=\"_blank\" id=\"11510629\">11510629</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Barkun AN, Bardou M, Kulpers EJ, et al, &ldquo;International Consensus Recommendations on the Management of Patients With Nonvariceal Upper Gastrointestinal Bleeding,&rdquo; <i>Ann Intern Med</i>, 2010, 152(2):101-113.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/20083829/pubmed\" target=\"_blank\" id=\"20083829\">20083829</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bell AD, Roussin A, Cartier R, et al, &ldquo;The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines,&rdquo; <i>Can J Cardiol</i>, 2011, 27(Suppl A):1-59.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/21640290/pubmed\" target=\"_blank\" id=\"21640290\">21640290</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Blume H, Donath F, Warnke A, et al, &ldquo;Pharmacokinetic Drug Interaction Profiles of Proton Pump Inhibitors,&rdquo; <i>Drug Saf</i>, 2006, 29(9): 769-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/16944963/pubmed\" target=\"_blank\" id=\"16944963\">16944963</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2014;109(7):950-966.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/24935270/pubmed\" target=\"_blank\" id=\"24935270\">24935270</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG clinical guideline: treatment of <i>Helicobacter pylori</i> infection. <i>Am J Gastroenterol</i>. 2017;112(2):212-239. doi: 10.1038/ajg.2016.563<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/28071659/pubmed\" target=\"_blank\" id=\"28071659\">28071659</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chey WD and Wong B, &ldquo;American College of Gastroenterology Guideline on the Management of <i>Helicobacter pylori</i> Infection,&rdquo; <i>Am J Gastroenterol</i>, 2007 102(8):1808-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/17608775/pubmed\" target=\"_blank\" id=\"17608775\">17608775</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cockayne SE, Glet RJ, Gawkrodger DJ, et al, &ldquo;Severe Erythrodermic Reactions to the Proton Pump Inhibitors Omeprazole and Lansoprazole,&rdquo; <i>Br J Dermatol</i>,1999, 141(1):173-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/10417548/pubmed\" target=\"_blank\" id=\"10417548\">10417548</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    de Jager CP, Wever PC, Gemen EF, et al, &ldquo;Proton Pump Inhibitor Therapy Predisposes to Community-Acquired <i>Streptococcus pneumoniae</i> Pneumonia,&rdquo; <i>Aliment Pharmacol Ther</i>, 2012, 36(10):941-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/23034135/pubmed\" target=\"_blank\" id=\"23034135\">23034135</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Erichsen R, Mikkelsen E, Pedersen L, et al, &quot;Maternal Use of Proton Pump Inhibitors During Early Pregnancy and the Prevalence of Hypospadias in Male Offspring,&quot; <i>Am J Ther</i>, 2012.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/22314213/pubmed\" target=\"_blank\" id=\"22314213\">22314213</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fallone CA, Chiba N, van Zanten SV, et al. The Toronto consensus for the treatment of <i>Helicobacter pylori</i> infection in adults. <i>Gastroenterology.</i> 2016;151(1):51-69.e14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/27102658/pubmed\" target=\"_blank\" id=\"27102658\">27102658</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17894652\"></a>Goldstein JL, Johanson JF, Hawkey CJ, et al, &ldquo;Clinical Trial: Healing of NSAID-Associated Gastric Ulcers in Patients Continuing NSAID Therapy &ndash; A Randomized Study Comparing Ranitidine With Esomeprazole,&rdquo; <i>Aliment Pharmacol Ther</i>, 2007, 26(8):1101-11.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/17894652/pubmed\" target=\"_blank\" id=\"17894652\">17894652</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kahrilas PJ, Shaheen NJ, Vaezi MF, et al, &ldquo;American Gastroenterological Association Medical Position Statement on the Management of Gastroesophageal Reflux Disease,&rdquo; <i>Gastroenterology</i>, 2008, 135(4):1383-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/18789939/pubmed\" target=\"_blank\" id=\"18789939\">18789939</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Katz PO, Gerson LB, and Vela MF, &quot;Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease,&quot; <i>Am J Gastroenterol</i>, 2013, 108(3):308-28.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/23419381/pubmed\" target=\"_blank\" id=\"23419381\">23419381</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kupiec TC, Aloumanis V, Ben M, et al, &ldquo;Physical and Chemical Stability of Esomeprazole Sodium Solutions,&rdquo; <i>Ann Pharmacother</i>, 2008, 42(9):1247-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/18614750/pubmed\" target=\"_blank\" id=\"18614750\">18614750</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lam JR, Schneider JL, Zhao W, Corley DA. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. <i>JAMA</i>. 2013;310(22):2435-2422.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/24327038/pubmed\" target=\"_blank\" id=\"24327038\">24327038</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lanza FL, Chan FK, and Quigley EM, &ldquo;Guidelines for Prevention of NSAID-Related Ulcer Complications,&rdquo; <i>Am J Gastroenterol</i>, 2009, 140(3):728-38.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/19240698/pubmed\" target=\"_blank\" id=\"19240698\">19240698</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lau JY, Leung WK, Wu JC, et al, &ldquo;Omeprazole Before Endoscopy in Patients With Gastrointestinal Bleeding,&rdquo; <i>N Engl J Med</i>, 2007, 356(16):1631-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/17442905/pubmed\" target=\"_blank\" id=\"17442905\">17442905</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lau JY, Sung JJ, Lee KK, et al, &ldquo;Effect of Intravenous Omeprazole on Recurrent Bleeding After Endoscopic Treatment of Bleeding Peptic Ulcers,&rdquo; <i>N Engl J Med</i>, 2000, 343(5):310-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/10922420/pubmed\" target=\"_blank\" id=\"10922420\">10922420</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lazarus B, Chen Y, Wilson FP, et al. Proton pump inhibitor use and the risk of chronic kidney disease. <i>JAMA Intern Med</i>. 2016:238-246.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/26752337/pubmed\" target=\"_blank\" id=\"26752337\">26752337</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levine GN, Bates ER, Blankenship JC, et al, &ldquo;2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions,&rdquo; <i>Circulation</i>, 2011, 124(23):e574-651.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/22064601/pubmed\" target=\"_blank\" id=\"22064601\">22064601</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lin HJ, Lo WC, Lee FY, et al, &ldquo;A Prospective Randomized Comparative Trial Showing That Omeprazole Prevents Rebleeding in Patients With Bleeding Peptic Ulcer After Successful Endoscopic Therapy,&rdquo; <i>Arch Intern Med</i>, 1998, 158(1):54-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/9437379/pubmed\" target=\"_blank\" id=\"9437379\">9437379</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Li J, Zhao J, Hamer-Maansson JE, et al, &quot;Pharmacokinetic Properties of Esomeprazole in Adolescent Patients Aged 12 to 17 Years With Symptoms of Gastroesophageal Reflux Disease: A Randomized, Open-Label Study,&quot; <i>Clin Ther</i>, 2006, 28(3):419-27.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/16750456/pubmed\" target=\"_blank\" id=\"16750456\">16750456</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Li X-Q, Anderson TB, Ahlstrom M, et al, &ldquo;Comparison of Inhibitory Effects of the Proton Pump-Inhibiting Drugs Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole, and Rabeprazole on Human Cytochrome P450 Activities,&rdquo; <i>Drug Metab Disp</i>, 2004, 32(8):821-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/15258107/pubmed\" target=\"_blank\" id=\"15258107\">15258107</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Moayyedi PM, Lacy BE, Andrews CN, Enns RA, Howden CW, Vakil N. ACG and CAG clinical guideline: management of dyspepsia. <i>Am J Gastroenterol</i>. 2017;112(7):988-1013. doi: 10.1038/ajg.2017.154.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/28631728/pubmed\" target=\"_blank\" id=\"28631728\">28631728</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Natsch S, Vinks MH, Voogt AK, et al, &ldquo;Anaphylactic Reactions to Proton-Pump Inhibitors,&rdquo; <i>Ann Pharmacother</i>, 2000, 34(4):474-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/10772433/pubmed\" target=\"_blank\" id=\"10772433\">10772433</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nexium (esomeprazole magnesium) [prescribing information]. Wilmington, DE: AstraZeneca; October 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nexium (esomeprazole magnesium) [product monograph]. Mississauga, Ontario, Canada: AstraZeneca Canada Inc; November 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nexium 24HR (esomeprazole sodium) [prescribing information]. Madison, NJ: Pfizer; received February 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nexium IV (esomeprazole sodium) [prescribing information]. Wilmington, DE: AstraZeneca; December 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pasternak B and Hviid A, &quot;Use of Proton-Pump Inhibitors in Early Pregnancy and the Risk of Birth Defects,&quot; <i>N Engl J Med</i>, 2010, 363(22):2114-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/21105793/pubmed\" target=\"_blank\" id=\"21105793\">21105793</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Paoluzi P, Iacopini F, Crispino P, et al, &ldquo;2-Week Triple Therapy for <i>Helicobacter pylori</i> Infection is Better Than 1-Week in Clinical Practice: a Large Prospective Single-Center Randomized Study,&rdquo; <i>Helicobacter</i>, 2006, 11(6):562-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/17083378/pubmed\" target=\"_blank\" id=\"17083378\">17083378</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"28101605\"></a>Rhodes A, Evans LE, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. <i>Intensive Care Med</i>. 2017;43(3):304-377.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/28101605/pubmed\" target=\"_blank\" id=\"28101605\">28101605</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sachar H, Vaidya K, Laine L. Intermittent vs continuous proton pump inhibitor therapy for high-risk bleeding ulcers: a systematic review and meta-analysis. <i>JAMA Intern Med</i>. 2014;174(11):1755-1762.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/25201154/pubmed\" target=\"_blank\" id=\"25201154\">25201154</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sung JJ, Barkun A, Kuipers EJ, et al, &ldquo;Intravenous Esomeprazole for Prevention of Recurrent Peptic Ulcer Bleeding: A Randomized Trial,&rdquo; <i>Ann Intern Med</i>, 2009, 150(7):455-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/19221370/pubmed\" target=\"_blank\" id=\"19221370\">19221370</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Talley NJ and Vakil N, &ldquo;Practice Parameters Committee of the American College of Gastroenterology. Guidelines for the Management of Dyspepsia,&rdquo; <i>Am J Gastroenterol</i>, 2005, 100(10):2324-37.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/16181387/pubmed\" target=\"_blank\" id=\"16181387\">16181387</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wolfe MM and Sachs G, &ldquo;Acid Suppression: Optimizing Therapy for Gastroduodenal Ulcer Healing, Gastroesophageal Reflux Disease, and Stress-Related Erosive Syndrome,&rdquo; <i>Gastroenterology</i>, 2000,118(2 Suppl 1):9-31.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zargar SA, Javid G, Khan BA, et al, &ldquo;Pantoprazole Infusion as Adjuvant Therapy to Endoscopic Treatment In Patients With Peptic Ulcer Bleeding: Prospective Randomized Controlled Trial,&rdquo; <i>J Gastroenterol Hepatol</i>, 2006, 21(4):716-21<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/16677158/pubmed\" target=\"_blank\" id=\"16677158\">16677158</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zhao J, Li J, Hamer-Maansson JE, et al, &ldquo;Pharmacokinetic Properties of Esomeprazole in Children Aged 1 to 11 Years With Symptoms of Gastroesophageal Reflux Disease: A Randomized, Open-Label Study,&rdquo; <i>Clin Ther</i>, 2006, 28(11): 1868-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/esomeprazole-drug-information/abstract-text/17213007/pubmed\" target=\"_blank\" id=\"17213007\">17213007</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9104 Version 259.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Special Alerts\" href=\"#F50836890\" class=\"outlineLink\">Special Alerts</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F166971\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F166972\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F166993\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F166975\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F2934196\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F166976\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F166977\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F166978\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F166946\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F166932\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F22149198\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F5940148\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F15241701\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F166948\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Usual Infusion Concentrations: Adult\" href=\"#F14472623\" class=\"outlineLink\">Usual Infusion Concentrations: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Usual Infusion Concentrations: Pediatric\" href=\"#F14472624\" class=\"outlineLink\">Usual Infusion Concentrations: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F166947\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F50558978\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F5730363\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F166938\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F166951\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F166936\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F166987\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F166940\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F166968\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F166955\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F166956\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F166957\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F166944\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F166935\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F166950\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F166954\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F166958\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9104|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=esomeprazole-patient-drug-information\" class=\"drug drug_patient\">Esomeprazole: Patient drug information</a></li><li><a href=\"topic.htm?path=esomeprazole-pediatric-drug-information\" class=\"drug drug_pediatric\">Esomeprazole: Pediatric drug information</a></li></ul></div></div>","javascript":null}